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Background
Several lines of evidence indicate that altered blood flow
regulation may contribute to the pathogenesis of glauco-
matous optic neuropathy. Recent data support the
hypothesis that the endothelin system is involved in the
processes that leads to vascular dysregulation in glau-
coma. Here, we tested the hypothesis that bosentan, a
dual endothelin receptor antagonist, increases ocular
blood flow in patients with glaucoma.
Materials and methods
Fourteen patients with primary open-angle glaucoma and
14 sex and age-matched healthy volunteers were included.
Both groups received bosentan 500 mg daily for 8 days.
Ocular hemodynamics were assessed at baseline and on
the last study day. Retinal vessel diameters and retinal red
blood cell velocity were recorded with a Retinal Vessel
Analyser and laser Doppler velocimetry, respectively.
Choroidal and optic nerve head blood flow were meas-
ured with laser Doppler flowmetry.
Results
Retinal arteries and veins showed a significant dilatation
after administration of bosentan in both groups (+5% to
8%). Retinal blood velocity and retinal blood flow
increased up to +45% after administration of bosentan in
both patients and healthy subjects. Administration of
bosentan increased choroidal (+12% to 17%) and optic
nerve head blood flow (+11% to 24%) in both groups.
The effect of bosentan on ocular blood flow parameters
was comparable between the two groups.
Conclusion
The data of the present study indicate that dual inhibition
of endothelin receptors increases ocular blood flow in
patients with glaucoma and healthy subjects. Further
studies are required to study the dose-response relation-
ship of this effect and to characterize the role of endothe-
lin receptor subtypes.
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